MedTrace Logo

Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.

NCT02797041 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-06-14

No results posted yet for this study

Summary

This observational, non-interventional, retrospective, multicenter, national study focuses on collecting information about the effectiveness and safety of bortezomib re-use at first relapse in MM patients already treated in their first line with a bortezomib-based regimen, re-challenged with the same drug according to current clinical practice and/or Italian SIE/SIES/GITMO, IMWG and/or NCCN Guidelines/Treatment Recommendations.

Data will be collected retrospectively from approximately 25 haematologic/oncologic sites in Italy. Approximately, data of up to 100 patients will be collected.

Conditions

Interventions

DRUG

Bortezomib

Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment

Sponsors & Collaborators

  • IRCCS Centro di Riferimento Oncologico della Basilicata

    lead OTHER

Principal Investigators

  • Pellegrino Musto, MD · IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (Pz), Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-03-31
Completion
2016-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02797041 on ClinicalTrials.gov